Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2020-12-01 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS 3 pages 121.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the FDA has granted Fast Track designation for a drug candidate (remestemcel-L) for treating COVID-19 related ARDS. It discusses clinical trial progress, regulatory status, and collaboration agreements. There are no financial statements, no detailed financial performance data, no voting results, no management changes, no earnings data, and no regulatory certifications. The content is primarily a regulatory and clinical development update. It is not a report or filing but an announcement of a regulatory milestone and clinical trial status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-01 English
6-K
Regulatory Filings
2020-12-01 English
Appendix 2A 15 pages 174.2KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and references to employee incentive schemes. This type of document is a regulatory announcement related to capital markets, specifically about the issuance and quotation of new securities. It is not a financial report, earnings release, or management discussion. It is a formal regulatory filing to the exchange about securities quotation. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive regulatory filing about capital changes.
2020-11-26 English
Mesoblast Chairman Message to 2020 AGM 2 pages 119.3KB
AGM Information Classification · 95% confidence The document is titled 'CHAIRMAN’S ADDRESS TO SHAREHOLDERS 2020 MESOBLAST ANNUAL GENERAL MEETING' and contains a detailed address from the chairman discussing the company's response to COVID-19, collaborations, product pipeline, and strategic outlook. It is clearly a speech or presentation given at the Annual General Meeting (AGM). There are no detailed financial statements or comprehensive annual report data present, nor is it a brief announcement or voting result. The content aligns with materials typically shared during an AGM to inform shareholders about company performance and strategy. Therefore, the document fits the category of AGM Information (AGM-R). The document length (8175 characters) supports it being a full address rather than a short announcement or notice.
2020-11-23 English
CEO Presentation to 2020 Annual General Meeting 20 pages 1.8MB
Regulatory Filings
2020-11-23 English
Results of Meeting 2 pages 219.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Results of Annual General Meeting Held 24 November 2020' and contains detailed voting results for resolutions passed at the AGM, including proxy votes and poll results. It references compliance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, which govern disclosure of voting results. The content is focused on the official announcement of voting outcomes rather than the AGM materials or the full annual report. The document length is short (3051 characters) and it provides detailed voting statistics, which aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the correct classification is DVA with high confidence.
2020-11-23 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.